Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Laser for Macular Edema in BRVO
NCT01189526Phase 3Unknown
- Sponsor
- Seoul Retina Investigator Group
- Start
- Jan 2009
- Primary completion
- Aug 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ranibizumab in macular edema (2 arms), sponsored by Seoul Retina Investigator Group. Primary endpoint: Best Corrected Visual Acuity at 48 weeks. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01189526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189526.